

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response:	0.5
---------------------	-----

1. Name and Address of Reporting Person* <u>Scholl Hendrik Peter</u> (Last) (First) (Middle) <u>GOTTHARDSTRASSE 26</u> (Street) <u>ZUG SWITZERLAND 6300</u> (City) (State) (Zip) <u>SWITZERLAND</u> (Country)	2. Issuer Name and Ticker or Trading Symbol <u>BELITE BIO, INC [BLTE]</u> Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>10/01/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>Chief Medical Officer</u> 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		200	D	\$163.625 ⁽³⁾	14,800	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		24	D	\$164.6408 ⁽⁴⁾	14,776	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		120	D	\$165.4935 ⁽⁵⁾	14,656	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		50	D	\$166.4368 ⁽⁶⁾	14,606	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		78	D	\$167.5876 ⁽⁷⁾	14,528	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		12	D	\$168.2117 ⁽⁸⁾	14,516	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		14	D	\$169.36 ⁽⁹⁾	14,502	I	By Bioptima Ltd.
American depositary share ⁽¹⁾	10/01/2026		S ⁽²⁾		2	D	\$170.02	14,500	I	By Bioptima Ltd.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

[illegible]

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Code V	5. Transaction Code (Instr. 8)	6. Amount or Number of Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3 and 4)	7. Date Exercisable and Expiration Date (Month/Day/Year)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Each American depositary share represents one ordinary share, par value US\$0.0001 per share of the issuer.													
2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/20/2016.													
3. Represents the weighted average price of shares sold at prices that ranged from \$163.38 to \$165.65. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
4. Represents the weighted average price of shares sold at prices that ranged from \$164.44 to \$164.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
5. Represents the weighted average price of shares sold at prices that ranged from \$165 to \$165.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
6. Represents the weighted average price of shares sold at prices that ranged from \$166.06 to \$166.77. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
7. Represents the weighted average price of shares sold at prices that ranged from \$167 to \$167.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
8. Represents the weighted average price of shares sold at prices that ranged from \$168.03 to \$168.42. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													
9. Represents the weighted average price of shares sold at prices that ranged from \$169.18 to \$169.51. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.													

/s/ Hendrik Peter Scholl

** Signature of Reporting Person

10/05/2026

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.